• Journal of Korean Medicine Rehabilitation
• /
• v.25 no.2
• /
• pp.73-80
• /
• 2015

Objectives To assess the safety of Shinbaro3 Pharmacopuncture by analyzing the potential single-dose intramuscular toxicity of Shinbaro3 Pharmacopuncture at various dose levels in SD (Spraque-Dawley) rats and Beagle dogs. Methods For evaluation of single-dose intramuscular toxicity of Shinbaro3 Pharmacopuncture, 40 SD rats (20 male and 20 famale) and 4 Beagle dogs (2 male and 2 female) were used. The rats were divided in four groups of 10 each, and treated intramuscularly with Shinbaro3 Pharmacopuncture at doses of 0.3, 0.6 and 1.2 mg/kg in distilled water, and distilled water as a vehicle control group, respectively. The Beagle dogs were divided into two groups of 2 each, and treated intramuscularly with Shinbaro3 Pharmacopuncture at doses of 0.15, and 0.3 mg/kg in distilled water, respectively, and signs of toxicity were observed. After a wash-out period of 3 days, the procedure was repeated with Shinbaro3 Pharmacopuncture at doses of 0.6, and 1.2 mg/kg in distilled water, respectively. Mortality, body weight changes, and necropsy findings were examined during the study period. Results There were no mortalities in either the SD rats or Beagle dogs. There were also no significant differences in adverse effects, body weight, or necropsy findings between the Shinbaro3 Pharmacopuncture and control groups. Conclusions There results suggest that the lethal dose 50 ($LD_{50}$) and approximate lethal dose (ALD) value of the test substance Shinbaro3 Pharmacopuncture are higher than 1.2 mg/kg in SD rats and Beagle dogs.

• Journal of Acupuncture Research
• /
• v.31 no.1
• /
• pp.43-50
• /
• 2014

Objectives : The purpose of this study is to compare the effect of Shinbaro pharmacopuncture treatment and bee venom pharmacopuncture treatment on cervical disc herniation and whiplash injury induced by traffic accident. Methods : This study was carried out on the 59 patients with whiplash injury by traffic accident and diagnosed as cervical disc herniation. The patients were divided into 2 groups ; Shinbaro pharmacopuncture group was treated with Shinbaro pharmacopuncture along with herbal medicine and general acupuncture. Bee venom pharmacopuncture group was treated with bee venom pharmacopuncture along with herbal medicine and general acupuncture. We measured verbal numerical rating scale(VNRS) and neck disability index(NDI) before the treatment and 1, 2, 3 weeks afterwards. Results : Shinbaro pharmacopuncture group and Bee venom pharmacopuncture both showed significant decrease in VNRS and NDI. Shinbaro pharmacopuncture group showed significant decrease over Bee venom pharmacopuncture group in VNRS decrement in the first week, while Bee venom pharmacopuncture group showed significant decrease over Shinbaro pharmacopuncture group in the secone week of treatment. Conclusion : According to the result of this study, it is suggested that Shinbaro pharmacopuncture group is more effective in reducing pain in the earlier period of treatment. Also suggests that further study on the effect of Shinbaro pharmacopuncture on patients diagnosed as cervical disc herniation after traffic accident for longer period of treatment.

• Journal of Acupuncture Research
• /
• v.30 no.5
• /
• pp.41-50
• /
• 2013

Objectives : This study was performed to compare the effects of Shinbaro pharmacopuncture therapy and bee venom pharmacopuncture therapy in lumbar disc herniation Methods : We compared treatment efficacy of 12 patients with Shinbaro pharmacopuncture therapy and 10 patients with bee venom pharmacopuncture therapy, all of whom were diagnosed with lumbar disc herniation using computed tomography(CT) or magnetic resonance imaging(MRI). We performed a retrospective comparison and analysis during the course of 21 days since admission. To evaluate the treatment efficacy, we recorded the temperatures of the opposite back, hip, and legs with visual analog scale(VAS, back and legs), pain rating scale(PRS), Oswestry disability index(ODI) and digital infrared thermal imaging(DITI) based on patients' medical records. Results : Both treatments were effective in reducing pain and improving functions for lumbar disc herniation patients in terms of VAS, PRS, ODI, DITI. Shinbaro pharmacopuncture group showed slightly better results than the bee venom pharmacopuncture group, but the difference was not significant. Conclusions : For the treatment of lumbar disc herniation, it is suggested that Shinbaro pharmacopuncture therapy is thought to be as effective as bee venom pharmacopuncture therapy without side effects, although further study would be necessary.

• Journal of Korean Medicine Rehabilitation
• /
• v.33 no.4
• /
• pp.125-144
• /
• 2023

Objectives This study aimed to investigate domestic clinical research trends in Shinbaro pharmacopuncture, identify diseases managed using Shinbaro pharmacopuncture, and suggest the direction for future studies to increase its clinical utilization. Methods This study used five steps proposed by Arksey and O'Malley and the PRISMA-extension for scoping reviews checklist. We examined published literature on Shinbaro pharmacopuncture studies reported until June 5, 2023, in the following eight databases (Research Information Sharing Service, Science ON, Oriental Medicine Advanced Searching Integrated System, KMBASE, The Society of Internal Korean Medicine, PubMed, EMBASE, and the Cochrane Library). The search terms used were 'Shinbaro' or 'Sinbaro'. Results A total of 47 studies were included in our analysis. Of these, 37 (78.7%) were interference time series studies. Shinbaro pharmacopuncture was the most frequently used treatment for lumbosacral disease (n=15). In the facial area, ST4 and ST6 were used in five out of six studies, and in the shoulder area, TE14 and LI15 were used in all studies. Nine of the 15 studies in the lumbosacral area used the EX-B2. The other parts mostly used the pressure points. Compared to other pharmacopuncture methods, the treatment effect was similar to that of bee venom, and faster than that of jungsongouhyul. Conclusions This is the first scoping review of Shinbaro pharmacopuncture therapy in South Korea. Studies with a high level of evidence based on sole treatment, large capacities, and standardization of Shinbaro pharmacopuncture need to be conducted to increase its clinical utilization.

• The Journal of Internal Korean Medicine
• /
• v.37 no.2
• /
• pp.389-396
• /
• 2016

Objective: This study investigates the clinical application of Shinbaro pharmacopuncture for trigger finger.Method: Because the effect of Shinbaro pharmacopuncture has been proven in various musculoskeletal cases, we treated a patient diagnosed with trigger finger using Shinbaro pharmacopunture. A 0-10 numerical rating scale (NRS) for pain and Quinnell’s classification for trigger finger were assessed before and after three Shinbaro pharmacopuncture treatments.Results: After treatments, the patient’s pain was controlled (without any side effects), and the NRS score decreased from 8 to 1. The Quinnell’s classification of trigger finger score also improved (from 3 to 1).Conclusion: This case has shown that Shinbaro pharmacopuncture treatment could be effective for treating the clinical symptoms of trigger finger.

• Journal of Acupuncture Research
• /
• v.34 no.3
• /
• pp.109-119
• /
• 2017

Objectives : The purpose of this report was to show that oriental therapy, specifically Shinbaro pharmacopuncture is effective for improvement of symptoms and and range of motion (ROM) in patients diagnosed with meniscus tears in the knee. Methods : Three patients were treated with herbal medicine, acupuncture, cupping, Shinbaro pharmacopuncture. The efficacies of the treatments in the three cases were assessed and the progress of the three cases were measured Numerical Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), European Quality of Life five dimensions dimensions (EQ-5D), and range of motion (ROM) measurements. Results : After all the treatments, NRS, WOMAC, and EQ-5D decreased. Active and passive ROM of the knee increased. Conclusion : These reports show the effect of Shinbaro pharmacopucture on a meniscus tear. Due to the small number of cases in this study, further case reports are needed.

• Journal of Acupuncture Research
• /
• v.32 no.4
• /
• pp.77-89
• /
• 2015

Objectives : To evaluate the safety of multiple-dose intramuscular Shinbaro Pharmacopuncture in male and female Sprague-Dawley(SD) rats over a period of 4 weeks(12 sessions). Methods : In order to test the safety of multiple-dose intramuscular Shinbaro Pharmacopuncture we used 40 healthy male and female 6-week old SD rats(male weight 171.79~196.37 g, female weight 127.93~146.43 g). Shinbaro Pharmacopuncture was administered intramuscularly to male and female SD rats at doses of 4.6 (low dose group, n=10), 9.2 (moderate dose group, n=10), and 18.5 mg/kg(high dose group, n=10), respectively. General symptoms, body weight changes, blood tests, biochemical testing, necropsy, organ weight and histopathogical findings were examined over a 4-week period. Results : 1. No mortalities or adverse effects were caused by the investigational substance were observed during the study period. 2. There was no significant difference in body weight caused by the the investigational substance across all groups. 3. No significant between-group difference was found to be caused by the investigational substance in blood tests and biochemical testing. 4. No abnormalities were detected by a necropsy examination with the unaided eye at the macro level after treatment with the investigational substance. 5. Difference in organ weight between groups caused by the investigational substance was not found. 6. All groups did not exhibit pathological findings caused by the investigational substance in histopathogical examination. Conclusions : According to these results, Shinbaro Pharmacopuncture has no systemic or organ toxicity with multiple-dose intramuscular administrations in male and female SD rats over a 4-week period (12 sessions). These results imply that no adverse effects are observed at a level (NOAEL) of Shinbaro Pharmacopuncture of 18.5 mg/kg.

• Journal of Korean Medicine Rehabilitation
• /
• v.25 no.3
• /
• pp.1-9
• /
• 2015

Objectives To evaluate Shinbaro Pharmacopuncture safety through analysis of potential single-dose intramuscular toxicity of Sinbaro Pharmacopucture in SD rats and Beagle dogs. Methods Single-dose intramuscular toxicity of Shinbaro Pharmacopuncture was assessed in accordance with Korea Food and Drug Administration Guidelines for toxicity testing of Medicinal Products. The SD rats were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 0, 4.6, 9.2, and 18.5 mg/kg, respectively. The Beagle dogs were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 2.3, and 4.6 mg/kg, respectively, and after 3 days, the procedure was repeated a second time at doses of 0.6, and 1.2 mg/kg, respectively, for toxicity testing. Mortality, change in body weight, and necropsy findings were examined for the study period. Results There were no mortalities, general symptoms, or body weight changes in the SD rats. While pyelectasis of the left kidney was observed in a male rat in the 4.6 mg/kg administration group, natural occurrence is common, and does not appear to be related with the test substance. No mortalities were observed in the Beagle dogs. In assessment of general symptoms, a female dog in the 9.2 mg/kg group displayed body weight decrease due to leftover food, but the change in body weight was within the normal range seen at 6~7 months, and the necropsy findings were not significant. The toxicity of the test substance appears to be minimal. Conclusions The results suggest that the lethal dose 50 ($LD_{50}$) and approximate lethaldose (ALD) value in single intramuscular administration of Shinbaro Pharmacopuncture in SD rats and Beagle dogs are higher than 18.5 mg/kg.

• Journal of Haehwa Medicine
• /
• v.26 no.1
• /
• pp.73-80
• /
• 2017

Objectives : The purpose of this research is to show the effectiveness of the Korean medical treatment on patients diagnosed with supraspinatus tendinosis, subacromial bursitis and subdeltoid bursitis treated by Korean medical treatment Including megadose shinbaro pharmacopuncture. Methods : We used megadose shinbaro pharmacopuncture on patients who received treatment at Bucheon Jaseng Korean medicine hospital from December, 2016 to January, 2017. Also we checked NRS, SPADI, range of motion(ROM) and shoulder physical examination to follow the scale showing the improvement of the symptoms of the patients. Results : All 4 patientes showed the improvement of NRS, SPADI range of motion(ROM) and shoulder physical examination. Conclusion : This research showed that megadose shinbaro pharmacopuncture was effective on the treatment of shoulder pain patients diagnosed with supraspinatus tendinosis, subacromial bursitis and subdeltoid bursitis.

• Journal of Korean Medicine Rehabilitation
• /
• v.25 no.4
• /
• pp.161-167
• /
• 2015

Objectives The objective of this study is to report the improved case of Korean medicine treatment with Shinbaro3 pharmacopuncture for supraspinatus tendinitis and subdeltoid bursitis. Methods We used Shinbaro3 pharmacopuncture with other Korean medicine treatment (acupuncture, herbal medicine, cupping and chuna) for this patient. This case is measured and assessed by Numerical Rating Scale (NRS), shoulder range of motion (ROM) and shoulder physical examination. Results The NRS decreased from 10 to 2 and the patient showed nearly full shoulder range of motion. Also physical examination of shoulder was improved. Conclusions Korean medicine treatment with Shinbaro3 pharmacopuncture is proved to be helpful to relieve pain and recover function on shoulder joint.